Trial Profile

A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Aug 2024 According to an ImmunityBio media release,the company has received regulatory approval to begin patient enrollment in India and company plans to submit an application to the South Africa regulatory authorities in Q3 2024.
30 Apr 2024 According to an ImmunityBio media release, companys Chief Medical Officer Sandeep Bobby Reddy, M.D., will present the latest findings from this trial at the AUA Annual Meeting, Sunday, May 5, 2024 from 10:32 to 10:40 am in the Learning Lab.
11 Apr 2024 Planned End Date changed from 1 Dec 2027 to 1 Dec 2038.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com